ReviewTranslational research : the journal of laboratory and clinical medicine2017
The metabolic syndrome and chronic kidney disease.
Review in Translational research : the journal of laboratory and clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 4 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2026Pooled it
- Burden of metabolic syndrome in the global adult HIV-infected population: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Prevalence of metabolic syndrome in patients with end-stage renal disease: a systematic review and meta-analysis.International urology and nephrology · 2024Pooled it
- The association between hypertriglyceridemic-waist phenotype and chronic kidney disease: a cohort study and meta-analysis.Scientific reports · 2022Pooled it
- The effect of dietary approaches to stop hypertension (DASH) diet on fatty liver and cardiovascular risk factors in subjects with metabolic syndrome: a randomized controlled trial.BMC endocrine disorders · 2024Trial
- Long-term metabolic-adiposity burden and cardiovascular risk: the cumTyG-WHtR in Chinese adults.BMC cardiovascular disorders · 2026Article
- N-Acetylcysteine Mitigates Renal Fibrosis by Modulating Inflammasome and Gluconeogenic Pathways Under Cardiometabolic Stress.Antioxidants (Basel, Switzerland) · 2026Article
- Rising deaths due to sepsis and renal failure: a 22-year analysis of mortality trends in the US from 1999 to 2020.International urology and nephrology · 2026Article
- Article
- The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.Acta biochimica Polonica · 2026Review
- Associations between metabolic indices and the prevalence of simple renal cysts among hospitalized patients with hypertension in Xinjiang, China: a large-scale cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
- Association Between Estimated Glucose Disposal Rate and Chronic Kidney Disease in Elderly Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study in Zhejiang, China.Clinical interventions in aging · 2026Article
- Development and validation of a prediction model for cardiovascular-kidney-metabolic syndrome progression: a multicenter study.Frontiers in nutrition · 2026Article
- Probiotic Kefir Improves Renal Disorders in Ovariectomized Female SHR with High Fructose Intake-Induced Metabolic Syndrome.Probiotics and antimicrobial proteins · 2026Article
- Association between metabolic syndrome and chronic kidney disease in the Brazilian population, a cross-sectional analysis.Scientific reports · 2025Article
- Triglyceride-glucose index and risk of renal function decline and death-censored renal allograft loss in kidney transplant recipients.Kidney research and clinical practice · 2025Article
- Impact of onset age of type 2 diabetes mellitus on risk of renal complications compared to age-matched non-diabetic patients: Two cohort studies in the United Kingdom and Hong Kong.Diabetes, obesity & metabolism · 2025Article
- Cardamom extract: An effective weapon in prevention of cardiorenal syndrome induced in rats by cisplatin and high-fat diet.World journal of nephrology · 2025Article
- A High-Fat Diet Increases Kidney Fibrosis Through Regulating TGF-β and PDGF-β Signaling Pathways in Normotensive and Hypertensive Rat Models.International journal of molecular sciences · 2025Article
- Exploring the common genetic basis of metabolic syndrome-related diseases and chronic kidney disease: insights from extensive genome-wide cross-trait analyses.BioData mining · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors including insulin resistance (IR), dyslipidemia, and hypertension, which may also foster development of chronic kidney disease. The mechanisms of MetS-induced kidney disease are not fully understood. The purpose of this review is to summarize recent discoveries regarding the impact of MetS on the kidney, particularly on the renal microvasculature and cellular mitochondria. Fundamental manifestations of MetS include IR and adipose tissue expansion, the latter promoting chronic inflammation and oxidative stress that exacerbate IR. Those in turn can elicit various kidney injurious events through endothelial dysfunction, activation of the renin-angiotensin-aldosterone system, and adipokine imbalance. Inflammation and IR are also major contributors to microvascular remodeling and podocyte injury. Hence, these events may result in hypertension, albuminuria, and parenchymal damage. In addition, dyslipidemia and excessive nutrient availability may impair mitochondrial function and thereby promote progression of kidney cell damage. Elucidation of the link between MetS and kidney injury may help develop preventative measures and possibly novel therapeutic targets to alleviate and avert development of renal manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.